whether it may be overcome by higher doses or longer therapies remains to be established.
Sir, Daptomycin is licensed in the USA and Europe for the treatment of complicated skin and soft tissue infections caused by Gram-positive organisms, at a dose of 4 mg/kg once daily, and right-sided endocarditis with associated bacteraemia, at a dose of 6 mg/kg once daily. 1 Daptomycin has 92% plasma protein binding in vitro, a volume of distribution of 0.097 L/kg and a plasma elimination half-life of 9 h and is primarily excreted unchanged by the kidneys. Patients with a creatinine clearance ,30 mL/min exhibit AUC values twice those of patients with normal renal function. Daptomycin is removed by haemodialysis (HD); 15% of an administered dose is eliminated in a 4 h HD session. Therefore, in patients with reduced renal function, including those receiving HD, the recommended daily dose interval is 48 h. 2 To our knowledge there is little published about the use of daptomycin in patients who undergo continuous renal replacement therapy (CRRT), and in only one case were plasma concentrations recorded. 3 A person in their thirties, who was previously well, was admitted to our Emergency Department following a motorcycle accident, having suffered extensive trauma. The patient was transferred to the intensive care unit following surgery and empirical antibiotic therapy of amoxicillin/clavulanic acid and clindamycin was commenced. On the fourth day of recovery the patient developed septic shock and acute renal failure. Blood cultures and wound swabs from the left leg were collected and CRRT was started. We used a LYNDA dialysis system (Bellco, Italy). The programme we used was continuous venous -venous haemofiltration (CVVH) 24 h/day, using a high-filtration polysulphone membrane (HFT 22, surface area 2.2 m 2 , Bellco) with a blood flow of 150 mL/min and a dialyser flow of 3000 mL/h (50% pre and 50% post).
Antibiotic therapy was changed to a combination of glycopeptide plus piperacillin/tazobactam. On the seventh day, blood cultures and wound swabs grew methicillinresistant Staphylococcus epidermidis (MRSE). An antimicrobial susceptibility test was carried out using the VITEK-2 system (bioMé rieux, Marcy l'Étoile, France). MRSE was susceptible to rifampicin, co-trimoxazole, linezolid, tigecycline and glycopeptides with an MIC of vancomycin of 2 mg/L. The MIC of daptomycin by Etest (AB Biodisk) was 0.125 mg/L. Informed consent was obtained from the patient's next of kin and therapy with daptomycin was started at a daily dose of 8 mg/kg; the other antibiotics were stopped. The high dose of daptomycin was chosen because of the elevated volume of distribution (which is typical of septic patients, together with lower plasma albumin concentrations) and because polysulphone daptomycin clearance is higher than for other types of ultrafiltration. 4 It was not possible to determine plasma concentrations of daptomycin, and we therefore decided to monitor plasma concentrations of creatinine phosphokinase (CPK), aspartate aminotransferase, alanine aminotransferase and lactate dehydrogenase to exclude myopathy, a wellrecognized adverse effect of daptomycin. Since CPK can be eliminated by CVVH, we also measured the ultrafiltrate concentrations of CPK. The plasma concentration of CPK always remained ≤200 IU/L (normal: 50 -397 IU/L) and the ultrafiltered CPK concentration never exceeded 86 IU/L. The patient's condition improved and therapy was discontinued after 14 days.
Dosing of antibiotics for patients in intensive care can be challenging, particularly when they undergo renal replacement therapy. Ideally, plasma concentrations should be checked regularly, but this may be impractical in real time. Data from in vitro models of CRRT suggest that a substantial amount of daptomycin can be removed. 4 ,5 Since we could not monitor antibiotic concentrations in order to avoid subtherapeutic exposure, we decided to use a higher daily dose (8 mg/kg) and no adverse effects were demonstrated. Despite the limitations of this report we suggest that higher doses can be given safely in CRRT, but patients should be closely monitored for evidence of myopathy. Further studies, with plasma monitoring, are required to refine dosage regimens for CRRT.
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